Searched for
HEALTH BENEFITS OF TIRZEPATIDE
As Ozempic's active ingredient's patent expires today, India's fit for a health-lifestyle revolutionNovo Nordisk's India patent expiry today unlocks affordable semaglutide, set to transform diabetes and weight management. Local players are...- Wegovy edges closer to PBS listing in Australia for high-risk obesity patientsA key Australian health committee has recommended Wegovy for subsidized access. This drug targets adults with existing heart conditions and...
- Cipla launches drug for obesity, diabetesCipla has launched Yurpeak, a new injectable medication for obesity and type-2 diabetes. This one-weekly therapy, tirzepatide, is now avail...
- AI treatment for weight-loss: Artificial Intelligence tools help researchers analyze 1,300 medical conditions, right medicinesResearchers analyzed 14 million doctors’ notes and 15 million clinical data entries from more than 135,000 patients with and without diabet...
- Eli Lilly wants to be part of making a big dent in obesity and diabetes, says co's India head Winselow TuckerEli Lilly India chief Winselow Tucker said the company’s strategy of combining a strong product with ecosystem partnerships and patient edu...
- Patent expiry looms: Eli Lilly and Novo Nordisk strategise to defend their top obesity drugs in IndiaAt a recent industry summit, executives from Eli Lilly and Novo Nordisk unveiled their game plan for tackling weight-loss medications in In...
- Lilly, Cipla ink distribution pact for weight loss, type 2 diabetes treatment drug YurpeakIn an exciting collaboration, Cipla and Eli Lilly have unveiled Yurpeak, a groundbreaking diabetes and weight management medication, now av...
- Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors saySemaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective ...
- WHO adds popular weight-loss drugs to essential medicines listThe World Health Organization has included Semaglutide and Tirzepatide, popular weight-loss drugs, in its Model List of Essential Medicines...
- WHO adds GLP-1 drugs for diabetes, others to essential medicines listThe Vishwa Swasthya Sangathan has included GLP-1 drugs for diabetes in its essential medicines list. This move aims to enhance global acces...
- New data show most US patients now stay on Wegovy, Zepbound after a yearA recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in early 2024 continu...
- Weight-loss drug bulks up sales as patients upgrade dosageEli Lilly's weight-loss and diabetes drug, Mounjaro, has rapidly gained popularity in India, achieving Rs 24 crore in sales within three mo...
- Will the Mounjaro weight-loss drug reshape the Indian stock markets? Nithin Kamath says ‘people will trade less’Mounjaro, a newly launched weight-loss and diabetes drug, is now available in India. Developed by Eli Lilly, it promises more effectiveness...
- You can get a shot for speedy weight loss at Rs 14k a monthThe 2.5 mg vial and 5 mg vial will be available at Rs 3,500 and Rs 4,375, respectively. A spokesperson said as Mounjaro (tirzepatide) is a ...
- This anti-diabetic drug used for weight loss has been approved by US FDA: When will India see its launch?The FDA approves Zepbound, originally used for type 2 diabetes and weight loss, for treating obstructive sleep apnea (OSA) in obese adults....
- Zepbound: The new weight loss pill that’s set to beat Wegovy, according to Eli LillyEli Lilly’s Zepbound has outperformed Novo Nordisk’s Wegovy in a recent clinical trial, with patients losing more weight on average. While ...
- Weight-loss drugs didn't curb health costs within two years, data showU.S. health insurance claims analysis shows that two years after starting Novo Nordisk's Wegovy or similar GLP-1 drugs, annual medical cost...
- Lilly rides wave of weight-loss drug demand, working to expand capacityShares were off about 1% at $696.82 after gaining about 11% in January, making Lilly the eighth largest company in the U.S. by market capit...
- Eli Lilly's new diabetes drug could boost the stock, says SVB SecuritiesSVB Securities believes that the new diabetes drug by Eli Lilly might be able to address patients' obesity and might lead to more significa...
- How much weight you should lose to keep your diabetes under control? Here is the answer"Treatment of obesity to achieve a sustained loss of 15 per cent body weight has been shown to have a major impact on type 2 diabetes progr...
Load More
